A systematic review of stereotactic radiotherapy ablation for primary renal cell carcinoma

Abstract

E 7 3 7What ' s known on the subject? and What does the study add? At present, little is known about the role of stereotactic ablative body radiotherapy in the treatment of primary renal cell carcinoma. The published evidence to date totals 126 patients worldwide. The majority of evidence is retrospective in nature.

A Review of Kidney Motion under Free, Deep and Forced-Shallow Breathing Conditions: Implications for Stereotactic Ablative Body Radiotherapy Treatment

“…Delivery of high ablative doses was shown to be safe and well tolerated by patients treated for lung and abdominal cancers (4)(5). The role of SABR treatment for primary kidney cancers is emerging with a recent review of the literature for SABR treatment in primary kidney tumors showing two year local control rates of between 86%-100% with a concurrent incidence of grade 3 toxicities of less than 4% (6). Whilst early reports of safety and efficacy appear promising, strategies to account for respiratory induced motion of the kidneys are limited.…”

Management of advanced kidney cancer: Canadian Kidney Cancer Forum (CKCF) consensus update 2017

“…In patients with medically inoperable, early-stage RCC, SBRT to the primary tumour results in very high local control rates. 86,87 Similar high local control rates of ~ 90% are observed when using SBRT to treat RCC metastases in various body sites (thoracic, abdominal, soft tissue, bone, brain). 88,89 Such data refutes the previously held notion that RCC is radio-resistant.…”

Comparative analysis for renal stereotactic body radiotherapy using Cyberknife, VMAT and proton therapy based treatment planning

“…The use of SBRT in the treatment of local RCC was first reported by Qian et al 5. who achieved a local control rate of 93% at a mean follow‐up of 12 months 6.…”

“…However, the successful use of both image‐guided conventional radiotherapy and more recently stereotactic radio‐surgery in the local treatment of extracranial and intracranial RCC metastases, respectively, challenged the role of radiation therapy in the management of RCC. While previous literature suggested that RCC is radio‐resistant to small fraction sizes,4 higher fraction dose delivered through Stereotactic Body Radiation Therapy (SBRT) can achieve promising rates of local control and acceptable toxicity 5…”